ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 132,100 shares, a decrease of 24.2% from the March 31st total of 174,300 shares. Based on an average daily volume of 321,900 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.1% of the shares of the stock are sold short.
A number of institutional investors and hedge funds have recently modified their holdings of PRPH. Zeke Capital Advisors LLC purchased a new position in shares of ProPhase Labs during the first quarter worth approximately $259,000. Northern Trust Corp raised its position in ProPhase Labs by 14.5% in the 4th quarter. Northern Trust Corp now owns 46,476 shares of the company’s stock worth $426,000 after purchasing an additional 5,870 shares during the period. FNY Investment Advisers LLC bought a new stake in ProPhase Labs in the first quarter worth $439,000. Wedge Capital Management L L P NC purchased a new stake in ProPhase Labs during the first quarter valued at about $880,000. Finally, Renaissance Technologies LLC grew its stake in shares of ProPhase Labs by 25.3% during the fourth quarter. Renaissance Technologies LLC now owns 275,010 shares of the company’s stock valued at $2,525,000 after buying an additional 55,500 shares during the last quarter. 3.92% of the stock is owned by institutional investors and hedge funds.
Several research firms recently issued reports on PRPH. TheStreet lowered ProPhase Labs from a “c-” rating to a “d” rating in a research note on Friday, April 16th. Dawson James began coverage on ProPhase Labs in a research report on Wednesday, January 20th. They set a “buy” rating and a $25.00 price target for the company. Finally, Zacks Investment Research upgraded shares of ProPhase Labs from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday.
ProPhase Labs (NASDAQ:PRPH) last released its quarterly earnings results on Tuesday, March 30th. The company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.21). ProPhase Labs had a negative net margin of 12.92% and a negative return on equity of 15.95%.
ProPhase Labs Company Profile
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand.
Recommended Story: What is the market perform rating?
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.